Grail Inc Revenue Growth Rates (GRAL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Grail Inc   (NASDAQ: GRAL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

GRAL's Revenue Growth by Quarter and Year

Grail Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GRAL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 44.69
1st Quarter March 40.79
FY 85.48





GRAL Revenue second quarter 2026 Y/Y Growth Comment
Grail Inc achieved in the second quarter 2026, above Company average Revenue growth of 25.74% year on year, to $ 44.69 millions.

Looking into second quarter 2026 results within Medical Laboratories industry 11 other companies have achieved higher Revenue growth. While Grail Inc ' s Revenue rise of 25.74% ranks overall at the positon no. 838 in the second quarter 2026.


GRAL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 13.99 % -45.89 % -
3rd Quarter September - 26.32 % - -
2nd Quarter June 25.74 % 11.17 % - -
1st Quarter March 28.11 % 19.16 % - -
FY   - 17.18 % 77.66 % -

Financial Statements
Grail Inc 's second quarter 2026 Revenue $ 44.69 millions GRAL's Income Statement
Grail Inc 's second quarter 2025 Revenue $ 35.54 millions Quarterly GRAL's Income Statement


GRAL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 20.48 % 33.51 % -
3rd Quarter September - 1.83 % -10.38 % -
2nd Quarter June 9.55 % 11.62 % 19.65 % -
1st Quarter March -6.44 % -16.76 % -62.2 % -
FY (Year on Year)   - 17.18 % 77.66 % -


Back to GRAL Growth rate Comparisons >> Back to GRAL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #178
Overall #838

Revenue Y/Y Growth Statistics
High Average Low
28.11 % 11.22 % -45.89 %
(Jun 30 2026)   (Sep 30 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #178
Overall #838
Revenue Y/Y Growth Statistics
High Average Low
28.11 % 11.22 % -45.89 %
(Jun 30 2026)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Grail Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
33.51 % 0.08 % -62.2 %
(Dec 31 2024)  


GRAL's II. Quarter Q/Q Revenue Comment
Grail Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 9.55%, to $ 44.69 millions, from $40.79 millions in the first quarter.

Within Medical Laboratories industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Grail Inc 's Revenue growth quarter on quarter, overall rank is 836.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #7
Healthcare Sector #126
Overall #836
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #7
Healthcare Sector #126
Overall #836
Revenue Q/Q Growth Statistics
High Average Low
33.51 % 0.08 % -62.2 %
(Dec 31 2024)  


GRAL's II. Quarter Q/Q Revenue Comment
Grail Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 9.55%, to $ 44.69 millions, from $40.79 millions in the first quarter.

Within Medical Laboratories industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Grail Inc 's Revenue growth quarter on quarter, overall rank is 836.


Grail Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 165.26 $ 156.12 $ 147.17 $ 141.83 $ 134.29
Y / Y Revenue Growth (TTM) 23.07 % 19.44 % 17.18 % -10.26 % -
Year on Year Revenue Growth Overall Ranking # 3166 # 2187 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 5.86 % 6.08 % 3.77 % 5.62 % 2.73 %
Seq. Revenue Growth (TTM) Overall Ranking # 2313 # 1928 # 1650 # 1805 # 0


Cumulative Revenue growth Comment
With 23.07% annual Revenue growth, Grail Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 424 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2187 to 3166.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 425
Overall # 3166

Revenue TTM Y/Y Growth Statistics
High Average Low
23.07 %
 12.36 %
-10.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2313
Cumulative Revenue growth Comment
With 23.07% annual Revenue growth, Grail Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 424 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2187 to 3166.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 425
Overall # 3166

Revenue TTM Y/Y Growth Statistics
High Average Low
23.07 %
12.36 %
-10.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 336
S&P 500 # 2313




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GRAL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions


About Grail Inc Revenue Growth Rates (GRAL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Grail Inc (CIK 1699031).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-054307
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Grail Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.